secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001213900-23-004263
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 3.03, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics extends Series A conversion price adjustment indefinitely; discloses 2023 budget of ~$21.7M
--------------------------------------------------------------------------------

- Conversion price (lower of closing price or 5-day avg) for Series A Preferred now indefinite per amendment with 3i, LP.
- Proposed 2023 budget: $4.9M milestone payments, $10.5M development costs, $6.3M G&A; total ~$21.7M.
- Company intends to finance budget through capital raising; no assurance of sufficient capital.
- Series A Preferred issued in May 2021; 3i also holds a secured promissory note from November 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/0001213900-23-004263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/ea172038-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-004263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer